PARP1 and cancer: However, recent studies found that the mechanisms behind different platinum drugs are diverse.4,7 For example, oxaliplatin, unlike cisplatin and carboplatin, has been shown to kill cancer cells through ribosomal biogenesis stress, but not DNA damage; this might explain distinct clinical implementation of oxaliplatin from cisplatin.7 Nevertheless, the mainstream view still believes that PARP inhibitors and cisplatin belong to the classic DNA damage agent.